Affimed NV
NASDAQ:AFMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Affimed NV
NASDAQ:AFMD
|
DE |
|
Chorus Ltd
NZX:CNU
|
NZ |
|
S
|
Shandong Denghai Seeds Co Ltd
SZSE:002041
|
CN |
|
N
|
Nalwa Sons Investments Ltd
NSE:NSIL
|
IN |
|
Bilcare Ltd
BSE:526853
|
IN |
|
Gandhi Special Tubes Ltd
NSE:GANDHITUBE
|
IN |
|
SThree PLC
LSE:STEM
|
UK |
|
A
|
Apollo Sindoori Hotels Ltd
NSE:APOLSINHOT
|
IN |
|
Geniee Inc
TSE:6562
|
JP |
|
Synergy Green Industries Ltd
NSE:SGIL
|
IN |
|
Verisk Analytics Inc
NASDAQ:VRSK
|
US |
|
F
|
FIBI Holdings Ltd
TASE:FIBIH
|
IL |
|
S
|
Seoyon TopMetal Co Ltd
KOSDAQ:019770
|
KR |
|
China Finance Online Co Ltd
OTC:JRJCY
|
CN |
|
Watsco Inc
NYSE:WSO.B
|
US |
|
F
|
Fonix Mobile PLC
F:FOS
|
UK |
|
Jayride Group Ltd
ASX:JAY
|
AU |
|
Ferrovial SA
MAD:FER
|
ES |
|
V
|
Viking Line Abp
OMXH:VIK1V
|
FI |
|
S
|
Swancor Advanced Materials Co Ltd
SSE:688585
|
CN |
Affimed NV
Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
